← Back to all trials
Recruiting
NCT07398664
H101 Plus TACE for r/m HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 20
Sponsor: West China Hospital
Location: West China hospital Chengdu Sichuan
Summary
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
Eligibility Criteria
Inclusion Criteria:
1. Age between 18 and under 80 years old.
2. Pathologically confirmed head and neck malignancies (including nasopharyngeal carcinoma, oral cavity cancer, oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, salivary gland cancer, nasal cavity and paranasal sinus cancer, etc.); patients who have failed at least two lines of standard treatment (including cetuximab and immuno check point inhibitors).
3. Expected survival ≥3 months.
4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-2.
5. Pre-treatment peripheral blood tests meet the following conditions: neutrophil count \>2000/mm³, platelet count \>100,000/mm³.
6. Pre-treatment liver and kidney function meet the following: bilirubin \90 mmHg).
8. Adverse reactions from prior anti-tumor treatments have not recovered to CTCAE version 5.0 Grade \
Source: ClinicalTrials.gov (NCT07398664). StuddyBuddy aggregates publicly available trial information.
